Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropsychiatric and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FOSB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FOSB Recombinant Protein (including DeltaFosB variant) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View FOSB Products |
| Gene Delivery | FOSB Promise-ORF / Lentivirus Full-length ORF for stable cell lines and AP-1 reporter assays. |
View FOSB Products |
| Benchmark Ab | Anti-FOSB Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View FOSB Products |
| Validator | FOSB siRNA Set For gene knockdown and specificity verification. |
View FOSB Products |
| Related Target A | JUN Crucial dimerization partner of FOSB to form the active AP-1 transcription factor complex. |
View JUN Products |
| Related Target B | FOS Homologous family member used to assess off-target selectivity of FOSB inhibitors. |
View FOS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dimerization Partner Cross-Reactivity | Human/Mouse ortholog proteins available with >95% purity for binding assays |
| FOS Family Subfamily Screening | Homolog panel proteins (FOS, FOSB, FOSL1, FOSL2) strictly verified by mass spectrometry |
| Lack of Controls | Sequence-verified biosimilar antibodies included for assay bench-marking |
| False Positives in Knockdown | Validated siRNA sets included for functional specificity checks |
Live FOSB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FOSB therapeutics is intensifying, with major players shifting focus from traditional small molecules to targeted protein degradation (PROTACs/molecular glues) and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the highly stable DeltaFosB splice variant, which is heavily implicated in chronic stress, drug addiction, and specific mesenchymal tumors such as epithelioid hemangioendothelioma (EHE).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (AP-1 Inhibitor) | Academic Institutes, Biotech | Addiction, Depression, Osteosarcoma | Dimerization Inhibition Assay (Need high-purity recombinant FOSB and JUN) |
| Targeted Protein Degradation (PROTAC) | Oncology Biotechs | Epithelioid Hemangioendothelioma (EHE) | Degradation Kinetics (Need Lentivirus-expressed FOSB for stable cell construction) |
| RNA Therapeutics (siRNA/ASO) | Neurology Biotechs | Neuropsychiatric Disorders, Cocaine Addiction | Knockdown Efficiency Validation (Need sequence-specific siRNA sets) |